Clinical trial · Interventional
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
A Randomized Control Trial of Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
NCT00814242CI-TRIAL-00021585completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will compare and analyze the difference between hepatectomy at deep and complex sites(adjacent to major blood vessels) of patients with HCC and PRFA prognosis, recovery after treatment as well as incidence of complications so as to establish treatment standards of HCC at these sites.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| percutaneous radiationfrequency ablation | Procedure | — | UNRESOLVED |
| surgical resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- hepatectomy
- description
- Patients with HCC adjacent to major blood vessels recieved radical resection.
- interventionNames
- Procedure: surgical resection
- type
- EXPERIMENTAL
- label
- percutaneous radiationfrequency ablation
- description
- CT or Ultrasound-guided percutaneous radiofrequency ablation
- interventionNames
- Procedure: percutaneous radiationfrequency ablation
Primary outcomes (1)
- measure
- tumor recurrence rate in one or two years; Disease-free survival;Overall survival.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Identify patients with HCC in accordance with the clinical diagnostic criteria of HCC passed at the Chines Eighth National Live Cancer Academic Conference. Patients with HCC shall be diagnosed with pathology. There is at least one measurable lesion. * Hepatoma involved in this research at complex site is located at the eighth segment of liver, the substantial depth of liver below hepatic integument adjacent to the trunk of inferior vena cava, hepatic vein and portal vein. The tumor is located at hepatic caudate lobe. The maximal diameter \< or=3m, AJCC/UICC-TNM stage is stage II and above. Lesions are determined by three senior hepatobiliary experts independently, therefore radical resection is possible. There is no possibility of extra-hepatic metastasis and tumor thrombus of portal vein, hepatic vein, vena cava and bile duct. * Criteria of liver function: Child A level, serum bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value. It's appropriate to perform liver resection and minimally invasive treatment. * No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal. * Patients who can understand this trial, male or female, aged 18-70 voluntarily participate in clinical trials and have signed information consent. Exclusion Criteria: * Patients with apparent cardiac, pulmonary, cerebric and renal dysfunction,which may affect the treatment of liver cancer. * Patients with other diseases which may affect the treatment mentioned here. * Patients with medical history of other malignant tumors. * Subjects participating in other clinical trials. * Women in pregnancy and breast-feeding. * Patients with tumor AJCC/UICC-TNM stage at IIIA period or below.
References
Publications (0)
Data not yet available
No reference posted for this study.